Op-Ed: Why the lack of diversity in drug industry leadership is hurting women and people of color
LA TimesIf you’re a woman or person of color, your health is being hurt by a lack of diversity in healthcare. Dr. Lynn Seely, who was then the female chief executive officer of Myovant, a biopharmaceutical company that develops new treatments for women’s diseases, was speaking about chronic pelvic pain and painful periods associated with endometriosis. A lack of diversity in healthcare leadership is directly related to the lack of progress on women’s health challenges. And in the investor community, which overwhelmingly funds early drug development projects, only 16% of investment partners are women — and less than 2% of those women are Black or Hispanic. If improving health and saving lives is the goal, the healthcare industry, especially pharma companies and their funders, should immediately make greater diversity a priority.
Discover Related
